#Premarket Parabolic Curve on Positive Drug Trial
Technicals:
1. Trading 12.30 in premarket as of writing, up 57.29%
2. Price broken through all of its MA's, and has established new highs in premarket
3. MACD is currently signaling bullish
Fundamentals:
https://www.marketwatch.com/story/clearside-biomedical-shares-surge-53-premarket-on-news-of-positive-trial-of-eye-disease-treatment-2018-03-05?siteid=yhoof2&yptr=yahoo
—
For the complete technical analysis on this swing trading set-up, including full price extensions and bullish/bearish targets, click here: compoundtrading.com/swing-trading-periodical-contact
1. Trading 12.30 in premarket as of writing, up 57.29%
2. Price broken through all of its MA's, and has established new highs in premarket
3. MACD is currently signaling bullish
Fundamentals:
https://www.marketwatch.com/story/clearside-biomedical-shares-surge-53-premarket-on-news-of-positive-trial-of-eye-disease-treatment-2018-03-05?siteid=yhoof2&yptr=yahoo
—
For the complete technical analysis on this swing trading set-up, including full price extensions and bullish/bearish targets, click here: compoundtrading.com/swing-trading-periodical-contact
Founder: EPIC Agentic AI | World's Best Autonomous Trading Software
dashboard.epicaitrader.com | epicaihub.io
Trading CL_F, NQ_F, BTC, ETH, SOL, TAO, SUI, XRP, Stock Basket
dashboard.epicaitrader.com | epicaihub.io
Trading CL_F, NQ_F, BTC, ETH, SOL, TAO, SUI, XRP, Stock Basket
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.
Founder: EPIC Agentic AI | World's Best Autonomous Trading Software
dashboard.epicaitrader.com | epicaihub.io
Trading CL_F, NQ_F, BTC, ETH, SOL, TAO, SUI, XRP, Stock Basket
dashboard.epicaitrader.com | epicaihub.io
Trading CL_F, NQ_F, BTC, ETH, SOL, TAO, SUI, XRP, Stock Basket
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.